Second Polish Pharma Co To Go Public
Around 56% of shares in the state-owned pharmaceutical company Kutnowskie Zaklady Farmaceutyczne Polfa are being offered to the Polish public this week.
The Polish Securities Commission has said in a statement that it had approved for public trading all 1.8 million Polfa shares, including a 1 million share public offering which is set to close on December 23. Also up to 258,000 shares or 14% of Polfa's capital would be offered to company employees. The price is to be announced later.
The company is the second pharmaceutical business to be sold off by the Polish State. In June it privatized Jelfa, which is now listed on the Warsaw bourse.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze